diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 9c63d864..958fa002 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -125,6 +125,12 @@ If GLP-1 + exercise combination produces durable weight maintenance (3.5 kg rega Aon's 192,000+ patient analysis shows the inflationary impact is front-loaded and time-limited: costs rise 23% vs 10% in year 1, but after 12 months medical costs grow just 2% vs 6% for non-users. At 30 months for diabetes patients, medical cost growth is 6-9 percentage points lower. This suggests the 'inflationary through 2035' claim may be true only for short-term payers who never capture the year-2+ savings, while long-term risk-bearers see net cost reduction. The inflationary impact depends on payment model structure, not just the chronic use model itself. + +### Additional Evidence (challenge) +*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20* + +India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% price reduction (₹3,000-5,000/month vs ₹8,000-16,000 branded), with analysts projecting 90% price reduction over 5 years. Patents also expire in 2026 in Canada, Brazil, Turkey, China. University of Liverpool shows production costs as low as $3/month. US patents hold until 2031-2033, creating geographic bifurcation where international markets experience deflationary pressure starting 2026 while US remains inflationary through 2033. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index 0c35f649..914b402e 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -49,6 +49,12 @@ The Trump Administration deal establishes a $50/month out-of-pocket maximum for Aon's commercial claims data (employer-sponsored insurance) shows strong adherence effects, but the sample is biased toward higher-income employed populations. The fact that even in this relatively advantaged cohort, adherence is the key determinant of cost-effectiveness supports the claim that affordability barriers in lower-income populations would be even more binding. + +### Additional Evidence (extend) +*Source: [[2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics]] | Added: 2026-03-20* + +OBBBA work requirements threaten to remove ~10M from Medicaid coverage precisely when international GLP-1 prices are dropping 50-90% but US prices remain patent-protected at $1,300/month through 2033. This creates structural access failure where coverage loss and price compression move in opposite directions for the population with highest metabolic disease burden. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.json b/inbox/queue/.extraction-debug/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.json new file mode 100644 index 00000000..0af0a198 --- /dev/null +++ b/inbox/queue/.extraction-debug/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md:set_created:2026-03-20", + "us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md:set_created:2026-03-20" + ], + "rejections": [ + "glp-1-international-patent-cliff-is-2026-2028-event-not-2030-creating-geographic-price-bifurcation.md:missing_attribution_extractor", + "us-medicaid-coverage-loss-and-glp-1-price-compression-create-inverse-access-dynamics-for-low-income-populations.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-20" +} \ No newline at end of file diff --git a/inbox/queue/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md b/inbox/queue/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md index 8094ae2a..17e3fab9 100644 --- a/inbox/queue/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md +++ b/inbox/queue/2026-03-20-stat-glp1-semaglutide-india-patent-expiry-generics.md @@ -7,9 +7,13 @@ date: 2026-03-17 domain: health secondary_domains: [] format: news analysis -status: unprocessed +status: enrichment priority: high tags: [glp1, semaglutide, generics, price-compression, india, patent-expiry, ozempic, wegovy] +processed_by: vida +processed_date: 2026-03-20 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -59,3 +63,18 @@ tags: [glp1, semaglutide, generics, price-compression, india, patent-expiry, oze PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Direct challenge to existing KB claim — patent expiration is happening NOW (India: March 20, 2026), not in 2030+. The "inflationary through 2035" claim needs geographic scoping at minimum and may be fundamentally wrong at the system level. EXTRACTION HINT: Extractor should propose a scope qualification or replacement for the existing GLP-1 claim, distinguishing US (patent-protected through 2031-2033) from international (price compression beginning 2026) and system-level (inflationary) from risk-bearing payer level (potentially deflationary by 2028-2030). + + +## Key Facts +- India semaglutide patent expired March 20, 2026 +- 50+ generic brands filed for Indian market launch March 21, 2026 +- Indian branded semaglutide price: ₹8,000-16,000/month (~$95-190) +- Indian generic launch price: ₹3,000-5,000/month (~$36-60), representing 50-60% reduction +- Named Indian generic manufacturers: Dr. Reddy's, Cipla, Sun Pharma (Noveltreat, Sematrinity), Zydus (Semaglyn), OneSource Specialty Pharma +- Semaglutide patents also expire in 2026: Canada, Brazil, Turkey, China +- US semaglutide patents: 2031-2033 +- University of Liverpool production cost analysis: $3/month ($28-140/year) +- Canadian branded Ozempic: ~$400 CAD/month +- Canadian projected generic price: $60-100 CAD/month within 12 months +- Felix Health (Canada) already forming generic Ozempic waitlist +- Oral Wegovy launched January 2026 at $149-299/month vs $1,300+ injectable branded